Cargando…
THU028 Novel Approach To Management Of Acromegaly With De Novo Oral Octreotide Or Combination Therapy With Cabergoline: A Case Series
Disclosure: A. Halstrom: None. G.A. Dobri: None. Acromegaly is a rare disorder characterized by tumoral hypersecretion of growth hormone (GH) leading to overproduction of insulin-like growth factor 1 (IGF-1). Patients present with physical changes, and systemic complications. Treatment involves surg...
Autores principales: | Halstrom, Amanda, Dobri, Georgiana Alina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10553422/ http://dx.doi.org/10.1210/jendso/bvad114.1108 |
Ejemplares similares
-
Addition of Cabergoline to Oral Octreotide Capsules May Improve Biochemical Control in Patients With Acromegaly Who Are Inadequately Controlled With Monotherapy
por: Fleseriu, Maria, et al.
Publicado: (2021) -
THU063 Somatostatin Analog Neoadjuvant Treatment Before Endoscopic Surgery For Growth-Hormone Producing Pituitary Adenomas Invading The Cavernous Sinus: Case Series, Systematic Literature Review And Meta-analysis
por: Rapoport, Benjamin, et al.
Publicado: (2023) -
THU057 Predictors Of Response To Oral Octreotide Capsules In Patients With Acromegaly In A Large Prospective International Trial
por: Fleseriu, Maria, et al.
Publicado: (2023) -
THU025 Acromegaly And Central Hyperthyroidism
por: Akhtar, Ahmad, et al.
Publicado: (2023) -
THU070 Randomized, Placebo-controlled Phase 3 Trial Protocol Assessing The Efficacy And Safety Of Octreotide Subcutaneous Depot (CAM2029) In Patients With Acromegaly
por: Ferone, Diego, et al.
Publicado: (2023)